Get the app
US › Healthcare

VistaGen Therapeutics Inc (VTGN)

US · Healthcare · Biotechnology

$0.23+1.30%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$1.5M
Revenue YoY
+504.9%
Net profit
$-13.0M
EPS
$-0.30
EPS estimate
$-0.29
Net margin
-882.8%

EPS came in at -0.30 against a street estimate of -0.29 — a miss of 3.4%.

Key statistics

Market cap
$10.8M
Forward P/E
0.0
P/B
0.44
Book value
$0.55
EPS (TTM)
$-1.66
52-week high
$5.14
52-week low
$0.20
50-day MA
$0.25
200-day MA
$0.80
Beta
0.39

Analyst view

Analysts rate VistaGen Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $1.00.

Shareholding

Insiders
0.37%
Institutions
31.05%

Largest institutional holders

FundStake
Orbimed Advisors LLC6.90%
Vanguard Capital Management, LLC3.55%
StemPoint Capital LP2.78%
ADAR1 Capital Management LLC1.69%
Acadian Asset Management LLC1.33%
Ikarian Capital, LLC1.17%
Two Sigma Investments LLC1.06%
Geode Capital Management, LLC1.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for VistaGen Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.